Crispr Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $12,669 | $10,181 | $1,458 | $864 |
Gross Profit | -130,045 | -34,391 | -48,791 | -58,500 |
EBITDA | -103,792 | -110,516 | -117,773 | -124,338 |
EBIT | -108,030 | -114,796 | -122,092 | -129,999 |
Net Income | -111,437 | -91,154 | -122,931 | -130,613 |
Net Change In Cash | 12,669 | 10,181 | 1,458 | 864 |
Free Cash Flow | -90,098 | -86,619 | -109,401 | -93,070 |
Cash | 192,027 | 291,337 | 423,308 | 355,188 |
Basic Shares | 96,741 | 96,514 | 96,051 | 89,925 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $3,510 | $35,000 | $370,000 | $436 |
Gross Profit | -229,449 | -75,250 | 239,750 | -109,814 |
EBITDA | -558,486 | -343,406 | -130,885 | -648,989 |
EBIT | -577,965 | -362,665 | -150,722 | -673,161 |
Net Income | -581,599 | -366,252 | -153,610 | -650,175 |
Net Change In Cash | 3,510 | 35,000 | 370,000 | 436 |
Cost of Revenue | -715,804 | |||
Free Cash Flow | -345,928 | -144,675 | -269,845 | -532,929 |
Cash | 355,188 | 298,257 | 389,477 | 211,885 |
Basic Shares | 89,925 | 84,359 | 79,220 | 77,746 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$1.15 |
2026-06-30 | -$0.94 |
2026-03-31 | -$1.28 |
2025-12-31 | -$1.37 |